Caitlin Hyland, Ph.D. is a patent agent for Duane Morris’ Intellectual Property Practice Group. Dr. Hyland assists attorneys with the prosecution of patent and trademark applications.
Dr. Hyland is a molecular and developmental biologist. Prior to joining the firm, she was Senior Biopharmaceutical Project Manager - Cell and Gene Therapies for Eurofins-Lancaster Laboratories, where she functioned as a liaison between client R&D scientists and internal laboratory and project management leaders and managed biopharmaceutical testing programs for 3 cell and gene therapy clients. She also has eight years of experience in CRISPR/Cas9 genome editing approaches.
Dr. Hyland earned a Ph.D. in Cell and Molecular Biology from Lehigh University in 2021. She is also a magna cum laude graduate of Moravian University.
- U.S. Patent and Trademark Office
- Lehigh University, Ph.D., Cell and Molecular Biology, 2021
- Moravian University, B.S., magna cum laude, 2015
- Duane Morris LLP
- Patent Agent, 2023-present
- Technical Advisor, 2021-2023
- Eurofins-Lancaster Laboratories
- Senior Biopharmaceutical Project Manager - Cell and Gene Therapies, 2021
- Lehigh University, Department of Biological Sciences
- Ph.D. Candidate, 2015-2021
- Co-author, "Everything Flows Downstream: Novel Signal Transduction Suspects in Cohesinopathies," In prep for submission to Developmental Cell
- Co-author, "Impaired Cx43 gap junction endocytosis causes cardiovascular defects in zebrafish," Molecular Biology of the Cell, 2021
- Co-author, "Connexin 43 gap junctional intercellular communication inhibits evx1 expression and joint formation in regenerating fins," Development, 2020